DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Anthropic Nears $30 Billion Funding Round at $900 Billion Valuation 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
SpaceX Shareholders Approve 5-for-1 Stock Split Ahead of Potential IPO 
Samsung, Union Edge Closer to Deal as Strike Threat Looms 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
Sonova Beats Profit Forecasts Despite Cochlear Implant Weakness 
Google, Blackstone Launch $5B AI Cloud Venture to Challenge Nvidia and CoreWeave 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
BOSTON, Sept. 21, 2016 -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast its corporate presentation at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27 at 4:00 p.m. Eastern Time.
A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with headquarters in Boston, is focused on bringing innovative medicines to people with renal disease. In December 2014, the company launched its first FDA-approved medicine, Auryxia® (ferric citrate) in the United States. In January 2014, ferric citrate was approved for use in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). For more information about Keryx, please visit www.keryx.com.
KERYX BIOPHARMACEUTICALS CONTACT: Lora Pike Senior Director, Investor Relations T: 617-466-3511 [email protected]
